ClinicalTrials.gg
TerminatedNCT04274907Updated Feb 11, 2021

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

A Phase 1 interventional study of Venetoclax and Pembrolizumab in Non Small Cell Lung Cancer and Cancer, sponsored by AbbVie. Terminated at 39 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-11.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Why this study was terminated
Company Decision

From the registry’s dates

  • Primary completion was Feb 2021, 5 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Carcinoma, Non-Small-Cell Lung by AbbVie — 8 open to participants now, 14 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · AbbVie.

Enrollment
44th of 46
2 · median 135
Started
2020
with 2 others
Phase 1
21 of 48
2 open now
Registered
32nd of 48
by date

Among the 48 studies in Carcinoma, Non-Small-Cell Lung by AbbVie, this one is the 44th largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2020, is one of 21 in phase 1, and was the 32nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 48 studies in Carcinoma, Non-Small-Cell Lung by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Carcinoma, Non-Small-Cell Lung by AbbVie, or all of them as a file.
02

Study summary

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy (how well the study drug works against the disease) of venetoclax in combination with pembrolizumab in participants with NSCLC.

Venetoclax is a drug that kills cancer cells by blocking a protein (part of a cell) that allows cancer cells to stay alive. Pembrolizumab is approved drug for the treatment of NSCLC. It works with your immune system to help fight certain cancers. The study is split into two portions - dose escalation and randomization. Participants are assigned one of the three treatment groups to receive pembrolizumab alone or in combination with venetoclax. Each group receives a different treatment. Participants who are at least 18 years of age with a diagnosis of NSCLC will be enrolled. Around 100 participants will be enrolled in the study in approximately 44 sites across United States.

Participants will receive intravenous (IV) infusion of pembrolizumab alone or in combination with oral venetoclax tablets.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Cancer

Keywords

  • Non Small Cell Lung Cancer (NSCLC)
  • Cancer
  • Venetoclax
  • Pembrolizumab
  • PD-L1 Expression
  • ABT-199
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented advanced or NSCLC with no known epidermal growth factor receptor (EGFR) sensitizing (activating) mutation or anaplastic lymphoma kinase (ALK) translocation.
  • At least one as defined by (RECIST) 1.1.
  • High tumor expression (tumor proportion score >= 50%) as determined by a Food and Drug Administration (FDA)-approved test.
  • Willing to provide tissue sample prior to start of study.
  • (ECOG) Performance Status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Received prior systemic treatment for their advanced or NSCLC. Participants who received or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the diagnosis of metastatic disease.
  • History of or ongoing interstitial lung disease or pneumonitis that required oral or intravenous (IV) .
  • Active disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. If a participant has signs/symptoms suggestive of SARS-CoV-2 infection, they should undergo molecular (e.g., polymerase chain reaction [PCR]) testing to rule out SARS-CoV-2 infection.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Dose Escalation Phase: Venetoclax + Pembrolizumab

    Participants will receive escalating doses of venetoclax in combination with pembrolizumab Dose A.

    Drug: Venetoclax · Drug: Pembrolizumab

  • Experimental
    Randomization Phase: Venetoclax + Pembrolizumab

    Participants will receive venetoclax at dose levels determined in the dose escalation phase in combination with pembrolizumab Dose A.

    Drug: Venetoclax · Drug: Pembrolizumab

  • Active comparator
    Randomization Phase: Pembrolizumab Monotherapy

    Participants will receive pembrolizumab Dose A

    Drug: Pembrolizumab

Interventions

  • Tablet: Oral

    Also known as: Venclexta, ABT-199

  • Intravenous (IV) Infusion

    Also known as: Keytruda

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose-Limiting Toxicities (DLTs)

    DLTs are adverse events that are considered to have a reasonable possibility of relationship to the administration of venetoclax and pembrolizumab and cannot be attributed by the investigator to a clearly identifiable cause such as disease progression, concurrent illness or concomitant medication.

    Time frame: Up to 28 Days

  2. Change in the Sum of the Longest Diameter (SLD)

    Change in the SLD is assessed by exposure-response modeling

    Time frame: Up to 35 Cycles (Each Cycle is 21 Days)

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of Venetoclax

    Maximum plasma concentration (Cmax) of venetoclax

    Time frame: Up to Cycle 1 (Each Cycle is 21 Days)

  2. Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax

    Time to maximum observed plasma concentration (Tmax) of venetoclax

    Time frame: Up to Cycle 1 (Each Cycle is 21 Days)

  3. Area Under the Plasma Concentration-Time Curve Over Time from 0 to 24 (AUC0-24) of Venetoclax in Plasma

    Area Under the Plasma Concentration-time Curve (AUC) from 0-24 (AUC0-24)

    Time frame: Up to Cycle 1 (Each Cycle is 21 Days)

  4. Objective Response Rate (ORR)

    ORR will be defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR).

    Time frame: Up to 35 Cycles (Each Cycle is 21 Days)

07

Study locations

39 sites
  • Univ of Alabama at Birmingham /ID# 214180
    Birmingham, Alabama 35233, United States
  • Arizona Oncology Associates, PC-HOPE (Rudasill) /ID# 216984
    Tucson, Arizona 85704, United States
  • St Jude Hospital dba St Joseph /ID# 212360
    Santa Rosa, California 95403, United States
  • Icri /Id# 217071
    Whittier, California 90603, United States
  • AdventHealth Cancer Institute - Orlando /ID# 214444
    Orlando, Florida 32804, United States
  • Georgia Regents University /ID# 217109
    Augusta, Georgia 30912, United States
  • Rush University Medical Center /ID# 212448
    Chicago, Illinois 60612, United States
  • University of Chicago DCAM /ID# 214319
    Chicago, Illinois 60637-1443, United States
  • Ingalls Memorial Hosp /ID# 214952
    Harvey, Illinois 60426, United States
  • Fort Wayne Medical Oncology /ID# 214954
    Fort Wayne, Indiana 46804, United States
  • Ashland-Bellefonte Cancer Ctr /ID# 218511
    Ashland, Kentucky 41101, United States
  • University of Louisville /ID# 215195
    Louisville, Kentucky 40202, United States
  • Central Maine Medical Center /ID# 216107
    Lewiston, Maine 04240, United States
  • Maryland Oncology Hematology /ID# 214131
    Columbia, Maryland 21044-3128, United States
  • University of Massachusetts Ca /ID# 218744
    Worcester, Massachusetts 01655, United States
  • Karmanos Cancer Institute /ID# 216986
    Detroit, Michigan 48201, United States
  • Henry Ford Health System /ID# 216385
    Detroit, Michigan 48202, United States
  • Univ of Mississippi Med Ctr /ID# 216429
    Jackson, Mississippi 39216-4500, United States
  • Washington University-School of Medicine /ID# 212355
    Saint Louis, Missouri 63110, United States
  • Methodist Estabrook Cancer Center /ID# 216910
    Omaha, Nebraska 68114-4108, United States
  • University of Nebraska Medical Center /ID# 216754
    Omaha, Nebraska 68198-6840, United States
  • Hackensack Univ Med Ctr /ID# 216484
    Hackensack, New Jersey 07601, United States
  • Atlantic Health System /ID# 217067
    Morristown, New Jersey 07960-6136, United States
  • Overlook Medical Center /ID# 219108
    Summit, New Jersey 07901-3533, United States
  • NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 218077
    New York, New York 10016-4744, United States
  • Weill Cornell Medical Center /ID# 216911
    New York, New York 10065, United States
  • University of Cincinnati Cancer Institute /ID# 216800
    Cincinnati, Ohio 45219-2364, United States
  • University Hospitals Cleveland /ID# 212241
    Cleveland, Ohio 44106, United States
  • The Ohio State University - The James /ID# 212298
    Columbus, Ohio 43210-1240, United States
  • Providence Cancer Center Oncology and Hematology Care - Westside Portland /ID# 215497
    Portland, Oregon 97225, United States
  • Allegheny General Hospital /ID# 214363
    Pittsburgh, Pennsylvania 15212, United States
  • Prisma Health Cancer Institute - Faris /ID# 217946
    Greenville, South Carolina 29605-4255, United States
  • Thompson Cancer Survival Ctr /ID# 217076
    Knoxville, Tennessee 37916, United States
  • Houston Methodist Hospital - Scurlock Tower /ID# 215481
    Houston, Texas 77030, United States
  • Utah Cancer Specialists /ID# 215496
    Salt Lake City, Utah 84106, United States
  • Virginia Cancer Specialists /ID# 214328
    Fairfax, Virginia 22031, United States
  • Massey Cancer Centre /ID# 212527
    Richmond, Virginia 23298, United States
  • Multicare Institute for Research and Innovation /ID# 217913
    Tacoma, Washington 98405, United States
  • Northwest Medical Specialties /ID# 218484
    Tacoma, Washington 98405, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Feb 2021, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2020
First posted
Feb 18, 2020
StartActual
Jun 30, 2020
Primary completionActual
Feb 2, 2021
CompletionActual
Feb 2, 2021
Last update
Feb 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04274907
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 18, 2020
Start date
Jun 30, 2020
Primary completion
Feb 2, 2021
Completion
Feb 2, 2021
Last update
Feb 11, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion